US 12,291,499 B2
Deuterated tryptamine derivatives and methods of use
Alex Nivorozhkin, West Roxbury, MA (US)
Assigned to Cybin IRL Limited, Dublin (IE)
Filed by CYBIN IRL LIMITED, Dublin (IE)
Filed on Mar. 8, 2024, as Appl. No. 18/600,018.
Application 18/600,018 is a continuation of application No. 18/493,231, filed on Oct. 24, 2023, granted, now 11,958,807.
Application 18/493,231 is a continuation of application No. 18/172,691, filed on Feb. 22, 2023, granted, now 11,834,410.
Application 18/172,691 is a continuation of application No. 17/564,707, filed on Dec. 29, 2021, granted, now 11,724,985, issued on Jul. 26, 2023.
Application 17/564,707 is a continuation of application No. 17/394,038, filed on Aug. 4, 2021, granted, now 11,242,318, issued on Feb. 8, 2022.
Application 17/394,038 is a continuation of application No. PCT/IB2021/054340, filed on May 19, 2021.
Claims priority of provisional application 63/157,118, filed on Mar. 5, 2021.
Claims priority of provisional application 63/114,738, filed on Nov. 17, 2020.
Claims priority of provisional application 63/026,939, filed on May 19, 2020.
Prior Publication US 2024/0270691 A1, Aug. 15, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 209/16 (2006.01); A61K 9/20 (2006.01); A61K 31/4045 (2006.01)
CPC C07D 209/16 (2013.01) [A61K 9/20 (2013.01); A61K 9/2054 (2013.01); A61K 31/4045 (2013.01); C07B 2200/05 (2013.01); C07B 2200/07 (2013.01)] 17 Claims
 
1. A pharmaceutical composition, comprising:
a compound of Formula (III-d), or a pharmaceutically acceptable salt thereof

OG Complex Work Unit Chemistry
wherein:
R2 is hydrogen;
R6 and R7 are hydrogen; and
R8 and R9 are —CD3.